Identification of reliable prognostic biomarkers is essential to improve risk stratification and clinical outcomes.<h4>Methods</h4>MRPL23 expression was evaluated as a potential prognostic biomarker in NSCLC using immunohistochemical analysis of tumor specimens from 110 patients and mRNA expression data from The Cancer Genome Atlas (TCGA) cohort. The gene discussed is MRPL23; the disease is neoplasm.